{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:58:02Z","timestamp":1785452282284,"version":"3.56.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the National Key Laboratory of Lead Druggability Research","award":["YJS2024050"],"award-info":[{"award-number":["YJS2024050"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bioprocess Biosyst Eng"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00449-026-03388-6","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:00:54Z","timestamp":1784268054000},"page":"2225-2237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["High-yield soluble expression and affinity-tag-free purification of growth hormone receptor antagonist B2036 in Escherichia coli"],"prefix":"10.1007","volume":"49","author":[{"given":"Haoju","family":"Hua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yapeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junteng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinuo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"3388_CR1","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/0167-5699(90)90139-Z","volume":"11","author":"JF Bazan","year":"1990","unstructured":"Bazan JF (1990) Haemopoietic receptors and helical cytokines. Immunol Today 11:350\u2013354","journal-title":"Immunol Today"},{"issue":"Suppl. 3","key":"3388_CR2","first-page":"103","volume":"60","author":"JJ Kopchick","year":"2003","unstructured":"Kopchick JJ (2003) History and future of growth hormone research. Horm Res 60(Suppl. 3):103\u2013112","journal-title":"Horm Res"},{"key":"3388_CR3","doi-asserted-by":"publisher","DOI":"10.1126\/science.1249783","volume":"344","author":"AJ Brooks","year":"2014","unstructured":"Brooks AJ, Dai W, O\u2019Mara ML et al (2014) Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science 344:1249783","journal-title":"Science"},{"key":"3388_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.yapd.2022.03.005","volume":"69","author":"M Danowitz","year":"2022","unstructured":"Danowitz M, Grimberg A (2022) Clinical indications for growth hormone therapy. Adv Pediatr 69:203\u2013217","journal-title":"Adv Pediatr"},{"key":"3388_CR5","first-page":"1141","volume":"58","author":"SL Franklin","year":"2011","unstructured":"Franklin SL, Geffner ME (2011) Growth hormone: the expansion of available products and indications. Pediatr Clin 58:1141\u20131165","journal-title":"Pediatr Clin"},{"key":"3388_CR6","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJM199910143411607","volume":"341","author":"ML Vance","year":"1999","unstructured":"Vance ML, Mauras N (1999) Growth hormone therapy in adults and children. N Engl J Med 341:1206\u20131216","journal-title":"N Engl J Med"},{"key":"3388_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/adc.2010.186205","volume":"97","author":"J Kirk","year":"2012","unstructured":"Kirk J (2012) Indications for growth hormone therapy in children. Arch Dis Child 97:63\u201368","journal-title":"Arch Dis Child"},{"key":"3388_CR8","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","volume":"358","author":"AJ Van Der Lely","year":"2001","unstructured":"Van Der Lely AJ, Hutson RK, Trainer PJ et al (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754\u20131759","journal-title":"Lancet"},{"key":"3388_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2023.102884","volume":"54","author":"L Haberbosch","year":"2023","unstructured":"Haberbosch L, Strasburger CJ (2023) Efficacy and safety of pegvisomant in the treatment of acromegaly. Arch Med Res 54:102884","journal-title":"Arch Med Res"},{"key":"3388_CR10","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1073\/pnas.88.8.3407","volume":"88","author":"BC Cunningham","year":"1991","unstructured":"Cunningham BC, Wells JA (1991) Rational design of receptor-specific variants of human growth hormone. Proc Natl Acad Sci U S A 88:3407\u20133411","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3388_CR11","first-page":"1716","volume":"86","author":"RJM Ross","year":"2001","unstructured":"Ross RJM, Leung KC, Maamra M et al (2001) Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab 86:1716\u20131723","journal-title":"J Clin Endocrinol Metab"},{"key":"3388_CR12","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","volume":"342","author":"PJ Trainer","year":"2000","unstructured":"Trainer PJ, Drake WM, Katznelson L et al (2000) Treatment of acromegaly with the growth hormone\u2013receptor antagonist pegvisomant. N Engl J Med 342:1171\u20131177","journal-title":"N Engl J Med"},{"key":"3388_CR13","first-page":"4013","volume":"83","author":"ME Wilson","year":"1998","unstructured":"Wilson ME (1998) Effects of estradiol and exogenous insulin-like growth factor I (IGF-I) on the IGF-I axis during growth hormone inhibition and antagonism. J Clin Endocrinol Metab 83:4013\u20134021","journal-title":"J Clin Endocrinol Metab"},{"key":"3388_CR14","doi-asserted-by":"crossref","unstructured":"Francis DM, Page R (2010) Strategies to optimize protein expression in E. coli. Curr Protoc Protein Sci 61 Unit 5.24.","DOI":"10.1002\/0471140864.ps0524s61"},{"key":"3388_CR15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.4014\/jmb.1412.12079","volume":"25","author":"MN Baeshen","year":"2015","unstructured":"Baeshen MN, Al-Hejin AM, Bora RS et al (2015) Production of biopharmaceuticals in E. coli: current scenario and future perspectives. J Microbiol Biotechnol 25:953\u2013962","journal-title":"J Microbiol Biotechnol"},{"key":"3388_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/0968-0004(91)90135-I","volume":"16","author":"LL Graham","year":"1991","unstructured":"Graham LL, Beveridge TJ, Nanninga N (1991) Periplasmic space and the concept of the periplasm. Trends Biochem Sci 16:328\u2013329","journal-title":"Trends Biochem Sci"},{"key":"3388_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1146\/annurev-micro-090110-102925","volume":"65","author":"M Merdanovic","year":"2011","unstructured":"Merdanovic M, Clausen T, Kaiser M, Huber R, Ehrmann M (2011) Protein quality control in the bacterial periplasm. Annu Rev Microbiol 65:149\u2013168","journal-title":"Annu Rev Microbiol"},{"key":"3388_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.pep.2016.12.001","volume":"131","author":"ACSCM Menezes","year":"2017","unstructured":"Menezes ACSCM, Suzuki MF, Oliveira JE et al (2017) Expression, purification and characterization of the authentic form of human growth hormone receptor antagonist G120R-hGH obtained in Escherichia coli periplasmic space. Protein Expr Purif 131:91\u2013100","journal-title":"Protein Expr Purif"},{"key":"3388_CR19","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1021\/acs.bioconjchem.0c00208","volume":"31","author":"Y Wang","year":"2020","unstructured":"Wang Y, Langley RJ, Tamshen K et al (2020) Long-acting human growth hormone receptor antagonists produced in E. coli and conjugated with polyethylene glycol. Bioconjug Chem 31:1651\u20131660","journal-title":"Bioconjug Chem"},{"key":"3388_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3389\/fmicb.2014.00063","volume":"5","author":"S Costa","year":"2014","unstructured":"Costa S, Almeida A, Castro A et al (2014) Fusion tags for protein solubility, purification and immunogenicity in Escherichia coli: the novel Fh8 system. Front Microbiol 5:63","journal-title":"Front Microbiol"},{"key":"3388_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pep.2005.03.016","volume":"43","author":"TR Butt","year":"2005","unstructured":"Butt TR, Edavettal SC, Hall JP, Mattern MR (2005) SUMO fusion technology for difficult-to-express proteins. Protein Expr Purif 43:1\u20139","journal-title":"Protein Expr Purif"},{"key":"3388_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1023\/B:JSFG.0000029237.70316.52","volume":"5","author":"MP Malakhov","year":"2004","unstructured":"Malakhov MP et al (2004) SUMO fusions and SUMO-specific protease for efficient expression and purification of proteins. J Struct Funct Genomics 5:75\u201386","journal-title":"J Struct Funct Genomics"},{"key":"3388_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.pep.2013.10.016","volume":"94","author":"CP Papaneophytou","year":"2014","unstructured":"Papaneophytou CP, Kontopidis G (2014) Statistical approaches to maximize recombinant protein expression in Escherichia coli: a general review. Protein Expr Purif 94:22\u201332","journal-title":"Protein Expr Purif"},{"key":"3388_CR24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.biotechadv.2005.04.004","volume":"23","author":"J Shiloach","year":"2005","unstructured":"Shiloach J, Fass R (2005) Growing E. coli to high cell density\u2014a historical perspective on method development. Biotechnol Adv 23:345\u2013357","journal-title":"Biotechnol Adv"},{"key":"3388_CR25","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1007\/s00253-019-09719-w","volume":"103","author":"N Emamipour","year":"2019","unstructured":"Emamipour N, Vossoughi M, Mahboudi F et al (2019) Soluble expression of IGF1 fused to DsbA in SHuffle\u2122 T7 strain: optimization of expression and purification by Box-Behnken design. Appl Microbiol Biotechnol 103:3393\u20133406","journal-title":"Appl Microbiol Biotechnol"},{"issue":"10","key":"3388_CR26","first-page":"1007","volume":"42","author":"RS Donovan","year":"1996","unstructured":"Donovan RS, Robinson CW, Glick BR (1996) Optimizing the expression of a monoclonal antibody fragment under the transcriptional control of the Escherichia coli lac promoter. Can J Microbiol 42(10):1007\u20131013","journal-title":"Can J Microbiol"},{"key":"3388_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12896-021-00732-4","volume":"22","author":"AB Khalilvand","year":"2022","unstructured":"Khalilvand AB, Aminzadeh S, Sanati MH et al (2022) Media optimization for SHuffle T7 Escherichia coli expressing SUMO-Lispro proinsulin by response surface methodology. BMC Biotechnol 22:1","journal-title":"BMC Biotechnol"},{"key":"3388_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-1-0716-3362-5_6","volume-title":"Protein Chromatography: Methods and Protocols","author":"GT Henehan","year":"2023","unstructured":"Henehan GT, Ryan BJ, Kinsella GK (2023) Approaches to avoid proteolysis during protein expression and purification. Protein Chromatography: Methods and Protocols. Springer US, New York, NY, pp 77\u201395"},{"key":"3388_CR29","first-page":"22","volume":"6753165 B1","author":"GN Cox","year":"2004","unstructured":"Cox GN et al (2004) Methods for making proteins containing free cysteine residues. US 6753165 B1:22","journal-title":"US"},{"key":"3388_CR30","first-page":"200","volume":"6","author":"JG Moloughney","year":"2012","unstructured":"Moloughney JG, Weisleder N (2012) Poloxamer 188 (p188) as a membrane resealing reagent in biomedical applications, recent Pat. Biotechnol 6:200\u2013211","journal-title":"Biotechnol"},{"key":"3388_CR31","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1039\/C9TB02271F","volume":"8","author":"Z Chen","year":"2020","unstructured":"Chen Z, Lv Z, Sun Y et al (2020) Recent advancements in polyethyleneimine-based materials and their biomedical, biotechnology, and biomaterial applications. J Mater Chem B 8:2951\u20132973","journal-title":"J Mater Chem B"},{"key":"3388_CR32","doi-asserted-by":"publisher","first-page":"105647","DOI":"10.1016\/j.pep.2020.105647","volume":"173","author":"G Guo","year":"2020","unstructured":"Guo G, Han J, Wang Y et al (2020) A potential downstream platform approach for WuXiBody-based IgG-like bispecific antibodies. Protein Expr Purif 173:105647","journal-title":"Protein Expr Purif"},{"key":"3388_CR33","first-page":"490","volume":"25","author":"W Li","year":"2004","unstructured":"Li W, Zhu LH, Wang EB et al (2004) Effect of two human growth hormone receptor antagonists on glomerulosclerosis in streptozotocin-induced diabetic rats. Acta Pharmacol Sin 25:490\u2013495","journal-title":"Acta Pharmacol Sin"},{"key":"3388_CR34","unstructured":"Cunningham BC, Lowman HB, Wells JA et al (2000) Method for inhibiting growth hormone action. US6057292"},{"key":"3388_CR35","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jbiotec.2006.07.012","volume":"127","author":"J Yin","year":"2007","unstructured":"Yin J, Li G, Ren X, Herrler G (2007) Select what you need: a comparative evaluation of the advantages and limitations of frequently used expression systems. J Biotechnol 127:335\u2013347","journal-title":"J Biotechnol"},{"key":"3388_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nrmicro1087","volume":"3","author":"S Wildt","year":"2005","unstructured":"Wildt S, Gerngross TU (2005) The humanization of N-glycosylation pathways in yeast. Nat Rev Microbiol 3:119\u2013128","journal-title":"Nat Rev Microbiol"},{"key":"3388_CR37","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3389\/fmicb.2014.00172","volume":"5","author":"GL Rosano","year":"2014","unstructured":"Rosano GL, Ceccarelli EA (2014) Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol 5:172","journal-title":"Front Microbiol"},{"key":"3388_CR38","first-page":"680654","volume":"9","author":"O G\u0105siorowska","year":"2021","unstructured":"G\u0105siorowska O et al (2021) Challenges associated with the formation of recombinant protein inclusion bodies in escherichia coli and strategies to address them for industrial applications. Front Bioeng Biotechnol 9:680654","journal-title":"Front Bioeng Biotechnol"},{"key":"3388_CR39","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1210\/endo.142.7.8242","volume":"142","author":"B Elena","year":"2001","unstructured":"Elena B, Jeay S, Kelly PA et al (2001) The proliferative and antiapoptotic actions of growth hormone and insulin-like growth factor-1 are mediated through distinct signaling pathways in the Pro-B Ba\/F3 cell line. Endocrinology 142:2968\u20132977","journal-title":"Endocrinology"},{"key":"3388_CR40","unstructured":"Nordisk ASN, Behrens C, Thygesen P (2024) Long-acting growth hormone receptor antagonist and use thereof, WO 2024\/235802 A1"}],"container-title":["Bioprocess and Biosystems Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00449-026-03388-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00449-026-03388-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00449-026-03388-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:04:11Z","timestamp":1785449051000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00449-026-03388-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3388"],"URL":"https:\/\/doi.org\/10.1007\/s00449-026-03388-6","relation":{},"ISSN":["1615-7591","1615-7605"],"issn-type":[{"value":"1615-7591","type":"print"},{"value":"1615-7605","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jianguang Lu holds stocks of Shanghai Duomirui Bio-tech Co., Ltd.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments involving recombinant proteins, chemical reagents, and biological materials were performed in accordance with institutional and national safety guidelines.","order":2,"name":"Ethics","label":"Safety","group":{"name":"EthicsHeading","label":"Declarations"}}]}}